XML 28 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1

Revenues (Tables)

3 Months Ended

Mar. 31, 2018

Segment Reporting [Abstract]

Summary of net revenue

The Company’s net revenues consisted of the following for the three months ended March 31, 2018 and 2017:

															Three months ended March 31,
															2018						2017
Products:
Acetadote															$	1,273,764					$	1,265,440
Omeclamox-Pak															141,392						645,325
Kristalose															3,269,901						2,386,591
Vaprisol															93,890						684,548
Caldolor															1,039,747						813,027
Ethyol															2,256,073						3,666,808
Totect															412,774						—
Other															100,064						175,016
Total net revenues															$	8,587,605					$	9,636,755

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration